PMID- 30046605
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20220331
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2018
DP  - 2018
TI  - Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography 
      for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with 
      Ranibizumab.
PG  - 7438083
LID - 10.1155/2018/7438083 [doi]
LID - 7438083
AB  - PURPOSE: To identify spectral-domain optical coherence tomography (SD-OCT) 
      predictive morphological features for the outcome of Ranibizumab therapy for 
      neovascular age-related macular degeneration (AMD). METHODS: This is a 
      retrospective multicentric study that involved 64 eyes with naive AMD. Patients 
      who received three monthly intravitreal injections of Ranibizumab were stratified 
      into (1) "responders" [>/= 5 letters gain on Early Treatment Diabetic Retinopathy 
      Study (ETDRS) scale] and (2) "nonresponders" (< 5 letters gain). Best-corrected 
      visual acuity (BCVA) and SD-OCT morphological features were compared at baseline 
      and one month after three consecutive injections of Ranibizumab. Univariate and 
      multivariate analyses were carried out to correlate these morphological features 
      with the change in BCVA. RESULTS: Among the 64 patients enrolled, 40 (62.5%) were 
      "responders" and 24 (37.5%) "nonresponders". Age, sex, and BCVA were comparable 
      between both groups. A multivariate correlational analysis found that subfoveal 
      choroidal thickness (SFCT) and the presence of pigment epithelial detachment 
      (PED) > 250 mum at baseline were two independent prognostic indicators of final 
      BCVA. No other SD-OCT morphological studied features seem to affect final BCVA 
      after Ranibizumab treatment. CONCLUSION: SFCT and the presence of PED > 250 mum 
      are two significant biomarkers that may predict improvement after Ranibizumab 
      therapy for AMD. These markers may guide ophthalmologists' treatment decision 
      under financial constraints and limited time.
FAU - Azar, Georges
AU  - Azar G
AUID- ORCID: 0000-0002-9808-5545
AD  - Eye & Ear Hospital International, Beirut, Lebanon.
AD  - Holy Spirit University of Kaslik (USEK), Faculty of Medicine, Kaslik, Lebanon.
AD  - Saint Joseph University (USJ), Faculty of Medicine, Beirut, Lebanon.
FAU - Wolff, Benjamin
AU  - Wolff B
AUID- ORCID: 0000-0003-4709-692X
AD  - Rothschild Ophthalmological Foundation, 25 rue Manin, 75940 Paris Cedex 19, 
      France.
FAU - De Bats, Flore
AU  - De Bats F
AUID- ORCID: 0000-0002-8916-7784
AD  - Pole Vision Center, Clinique du Val-d'Ouest, 39 chemin de la Vernique, 69130 
      Ecully, France.
FAU - Halfon, Jeremie
AU  - Halfon J
AD  - Halles de Tours Ophthalmological Center, 13 place Gaston-Paillhou, 37000 Tours, 
      France.
FAU - Streho, Mate
AU  - Streho M
AD  - Explore Vision Center, 2 rue Grandes-Terres, 92500 Rueil-Malmaison, France.
FAU - Tick, Sarah
AU  - Tick S
AD  - Quinze-Vingts Ophthalmology National Center, 28 rue de Charenton, 75571 Paris 
      Cedex, France.
FAU - Castelnovo, Laurent
AU  - Castelnovo L
AD  - Maison Rouge Ophthalmological Center, 6 rue de l'Eglise, 67000 Strasbourg, 
      France.
FAU - Michel, Guillaume
AU  - Michel G
AD  - Maison Rouge Ophthalmological Center, 6 rue de l'Eglise, 67000 Strasbourg, 
      France.
FAU - Masse, Helene
AU  - Masse H
AD  - Nantes University Hospital Center, 8 quai Moncousu, 44000 Nantes, France.
FAU - Vasseur, Vivien
AU  - Vasseur V
AD  - Rothschild Ophthalmological Foundation, 25 rue Manin, 75940 Paris Cedex 19, 
      France.
FAU - Sahyoun, Marwan
AU  - Sahyoun M
AD  - Eye & Ear Hospital International, Beirut, Lebanon.
AD  - Holy Spirit University of Kaslik (USEK), Faculty of Medicine, Kaslik, Lebanon.
AD  - Saint Joseph University (USJ), Faculty of Medicine, Beirut, Lebanon.
FAU - Mauget-Faysse, Martine
AU  - Mauget-Faysse M
AD  - Rothschild Ophthalmological Foundation, 25 rue Manin, 75940 Paris Cedex 19, 
      France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180626
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Female
MH  - France
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Ranibizumab/*therapeutic use
MH  - Retrospective Studies
MH  - *Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity
MH  - Wet Macular Degeneration/diagnostic imaging/*drug therapy
PMC - PMC6038676
EDAT- 2018/07/27 06:00
MHDA- 2019/01/15 06:00
PMCR- 2018/06/26
CRDT- 2018/07/27 06:00
PHST- 2018/01/21 00:00 [received]
PHST- 2018/05/06 00:00 [accepted]
PHST- 2018/07/27 06:00 [entrez]
PHST- 2018/07/27 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/06/26 00:00 [pmc-release]
AID - 10.1155/2018/7438083 [doi]
PST - epublish
SO  - Biomed Res Int. 2018 Jun 26;2018:7438083. doi: 10.1155/2018/7438083. eCollection 
      2018.